0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Coagulation factor XI

Coagulation factor XI

Coagulation factor XI Molecule Information

Name:Coagulation factor XI
Target Synonym:FXI,F11,PTA,Coagulation Factor XI,Plasma Thromboplastin Antecedent,EC 3.4.21.27,Factor XI,Coagualtion Factor XI,EC 3.4.21,EC:3.4.21.27
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Approved

Coagulation factor XI Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FXI-H52H5 Human Human Coagulation factor XI / FXI Protein, His Tag (active enzyme)
FXI-H52H5-structure
FXI-H52H5-sds

Coagulation factor XI Molecule Synonym Name

Coagulation factor XI,FXI,PTA,F11

Coagulation factor XI Molecule Background

Coagulation factor XI is also known as F11, PTA and FXI. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Factor XI is synthesized in the liver and circulates in the plasma as a disulfide bond-linked dimer complexed with high molecular weight kininogen. Selective cleavage of Arg-|-Ala and Arg-|-Val bonds in factor IX to form factor IXa.  Factor XI is converted into XIa via either the contact phase of blood coagulation or thrombin-mediated activation on the platelet surface. The resulting XIa converts factor IX into IXa, which subsequently activates factor X into Xa.

Coagulation factor XI References

Coagulation factor XI Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Factor XI concentrate (factor XI deficiency), CSL Behring Approved Csl Behring Llc Australia Factor XI Deficiency s:15:"Csl Behring Llc"; 2014-07-01 Factor XI Deficiency Details
Human coagulation Factor XI (LFB) Approved Lfb Biotechnologies Hemoleven EU Factor XI Deficiency s:23:"Lfb Biotechnologies Sas"; 1999-07-01 Factor XI Deficiency Details

Coagulation factor XI Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
IONIS-FXI-LRX ION-957943; IONIS-FXI-LRx Phase 1 Clinical Ionis Pharmaceuticals Inc Thrombosis Details
Factor XIa Inhibitor (Bayer) Factor XIa Inhibitor (Bayer) Phase 1 Clinical Bayer Ag Blood Coagulation Disorders Details
BMS-262084 BMS-262084 Phase 1 Clinical Bristol-Myers Squibb Company Thrombosis Details
BAY-1831865 AB-012; BAY-1831865 Phase 1 Clinical Aronora Thrombosis Details
IONIS-FXIRX FXI-ASO; ISIS-FXIRX; BAY-2306001; IONIS-FXIRX; ISIS-404071; ISIS-416858 Phase 2 Clinical Ionis Venous Thromboembolism; Thrombosis Details
ONO-7684 ONO-7684 Phase 1 Clinical Ono Pharmaceutical Co Ltd Venous Thromboembolism Details
Xisomab 3G3 (Oregon Health & Science University) AB-022; AB-023 Phase 2 Clinical Oregon Health & Science University Thrombosis Details
BMS-962212 BMS-962212; BMS-96221202; BMS-962212-02 Phase 2 Clinical Bristol-Myers Squibb Company Thrombosis Details
ONO-7269 ONO-7269 Phase 1 Clinical Ono Pharmaceutical Co Ltd Cerebral Infarction Details
BAY-1213790 BAY-1213790 Phase 2 Clinical Bayer Ag Thromboembolism; Thrombosis Details
Osocimab BAY-1213790; BAY1213790 Phase 2 Clinical Bayer Ag Thromboembolism Details
BAY-2433334 BAY-2433334 Phase 2 Clinical Bayer Ag Myocardial Infarction; Stroke; Thromboembolism; Atrial Fibrillation Details
BMS-986177 JNJ-3093; BMS-986177; JNJ-70033093 Phase 2 Clinical Bristol-Myers Squibb Company Kidney Diseases; Stroke; Thromboembolism; Ischemic Attack, Transient; Thrombosis Details

This web search service is supported by Google Inc.

totop